The Aplastic Anaemia Trust is governed by a Board of Trustees, with the day-to-day running of the charity the responsibility of the CEO, working with the Patient Support Co-ordinator and a group of dedicated volunteers.

Sven Moos – Chair

Sven has worked in corporate finance and banking for 30 years in the UK, the US and in Germany. He was a trustee of the AAT from 2007 to 2014 and re-joined in early 2017. He supports the AAT as he was diagnosed with a related disease to AA, PNH, and was successfully treated at St George’s London by Professors Ted Gordon-Smith and Judith Marsh and their colleagues in 2001. Sven has seen that the AAT is able to make a significant contribution to fighting the disease by funding research as well as easing the anxieties, concerns and worries of patients as they cope with the illness. He is committed to supporting the AAT to allow it to intensify its activities significantly by ensuring it has the structure to grow and to enhance its fund-raising capabilities.


Prof.Ghulam Mufti

Professor Ghulam J Mufti is head of the department of haematological medicine at Guy’s, King’s and St Thomas’s hospitals, King’s College London, with a team of 13 professors, 6 senior lecturers/lecturers and approximately 100+ research staff.  In addition, Professor Mufti is the Clinical Director of Laboratories Sciences and a non-executive director of King’s College Hospital NHS Foundation Trust.

Professor Ghulam Mufti has extensive clinical and research expertise in leukaemias, lymphomas and in particular myelodysplastic syndromes, for which he is internationally renowned.    His particular area of research has focused on molecular aberrations in MDS/AML and the identification of novel therapies that include gene and cell-based therapies.  He has published 400+ papers and chapters in scientific journals and textbooks on leukaemias and MDS.

He heads the research groups at King’s working on the molecular genetics of MDS/aplastic anaemia/AML and is a member of the working group that produced national and intern
ational guidelines on the treatment and prognosis of MDS.  He is a founding member and chair of the UK MDS Forum.  He is also a member of the European Bone Marrow Transplantation Group and a founding member of the Board of the International Myelodysplastic foundation, for which his department at King’s College Hospital is a recognised Centre of Excellence. The department is also a centre of excellence for Leukaemia Lymphoma Research and is the largest allogeneic bone marrow transplant centre in the UK, and the only gene and cell-based therapies centre for myeloid leukaemia and allied diseases.


Prof. Judith Marsh

Judith Marsh is a Professor of Clinical Haematology and Consultant Haematologist with specialist interest in aplastic anaemia disorders. She qualified from Birmingham University and prior to being appointed at King’s, worked at St George’s Hospital/ St George’s University of London as Professor of Clinical Haematology/Honorary Consultant Haematologist, Kingston University as visiting Professor. Professor Marsh was Co-chairman of the Centre of International Blood and Marrow Transplant Research for nearly 10 years and currently chairs the writing board for British Committee for Standards in Haematology. Professor Marsh is Chairman of the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party and a member of the CIBMTR for International Affairs.


Ted was a Founder Trustee of the charity and Chair of the AAT 2006-2017.

He was instrumental in setting up a bone marrow transplantation unit at the Hammersmith Hospital in 1972, and launching the Marrow Environment Fund, with friends and family members of patients suffering from rare bone marrow failures. This grew into the Aplastic Anaemia Trust in the 90s, when Ted moved to St George’s to set up a department devoted to the bone marrow failure syndromes of which acquired Aplastic Anaemia was a particular but not exclusive interest. Fantastic advances have been made since then in understanding and treating acquired and constitutional AA. The AAT was hugely important in establishing the unit at St George’s and by engendering interest by the work in other units throughout the UK,  has put the country at the forefront of research and treatment of these rare syndromes in the International community.

Ted is currently- Emeritus Professor of Haematology, St George’s, University of London and Honorary Consultant Haematologist, St George’s NHS Trust, Retired December 2013.


Paul Cossell

Paul Cossell has worked in the construction industry for over 30 years, starting as a Quantity Surveyor.  The past 21 years have been with ISG plc, a specialist international construction services provider operating in 21 countries and employing approx. 2800 people.  Paul was appointed CEO of ISG in early 2016 when the company was privatised following a takeover by an American investor.

Paul has been married for 28 years and has two grown up daughters.  His hobbies include cycling, hiking and running, and he is a season ticket holder of Brentford FC.

Paul’s commitment to the AAT is motivated by the fact his wife was diagnosed with Aplastic Anaemia in 1983.  Initially Paul took part in several charity events organised by the AAT until in 2007 when he became a Trustee of the charity.  Paul took a break from being a Trustee between late 2014 and early 2017 but has now recommitted for at least 3 more years.


Jane Zucker

Jane worked as a partner in a city law firm specialising in media law until 2003. She has since left private practice and now sits as a lawyer on various tribunals. Jane is married, with a grown-up son and lives in London. She was diagnosed 20 years ago with a type of bone marrow failure and was treated by Professor Ted Gordon Smith and his team at St George’s hospital who managed her condition.  She became a trustee of the AAT 3 years ago.  Jane enjoys gardening, cooking and travelling.


Elaine Hanham


Grazina joined the AAT in January 2018 as its new CEO and brings with her extensive experience of patient-focused and innovative support provision, business strategy development, research and organisational excellence obtained in the not-for-profit and public sectors. Most recently, Grazina was the Group Director of Performance, Quality and Innovation at the Richmond Fellowship, a national mental health services provider, where she was instrumental in the organisation’s growth, improvement and journey towards greater user focus. Grazina lives in Cambridgeshire with two sons, enjoys the theatre, keeping fit and baking.  You can contact Grazina on gberry@theaat.org.uk


Bryony Partridge

Bryony set up a support group in 1997 for aplastic anaemia patients and their families following the diagnosis of her three year-old daughter Amy in 1995. In 2000 she joined up with the Marrow Environment Fund (MEF) to form the Aplastic Anaemia Trust.

Having experienced aplastic anaemia as a carer, Bryony can empathise with patients and provides information and much-needed emotional support.